Health FP7 Avdelingsdirektør Mari K. Nes Oslo 3. mai 2011
FP7 HEALTH - hovedområdene i det tematiske programmet Pillar 1 Bioteknologi, generiske metoder og medisinske teknologier Pillar 2 Translasjonsforskning de store folkesykdommene Pillar 3 Forebyggende helse og helsetjenesteforskning The Innovative Medicines Initiative Pillar 4 Implementering av FP7&EU politikk: fremtidige behov, formidling Programmet adresserer grunnleggende forskning, anvendt forskning, translasjonsforskning samt kliniske studier
FP7 Health 2007 2013 Overordnede mål Bedre helsen for Europas innbyggere Øke konkurranseevnen til europeisk helserelatert industri Adressere globale helseutfordringer
Health 6. utlysning (prosjektstart 2012) Fokus på innovasjon Arbeidsprogrammet (WP) er innrettet for å støtte implementeringen av «Innovation Union» Gi kunnskap som gir innovative produkter, prosesser og tjenester inkludere pilot-, demonstrasjons- og verifiseringsprosjekter EIP (European Innovation Partnership)
Health 6. utlysning Prioriteringer Aktiv og sunn aldring SMB-relevant forskning Medisinske teknologier Sjeldne sykdommer Forskerdrevne kliniske studier Formidling og resultatspredning
Health 6. utlysning Strategiske valg Konsentrasjon av midlene mange underområder lukket Ca 35 temaer/problemstillinger («topics») Budsjett på ca 620 mill Euro High Impact Project (HIP) på «rare diseases»? Én utlysning («call») og to-trinns behandling av alle søknader
Health 6. utlysning Annen viktig informasjon Internasjonalt samarbeid (med tredje land) Sammen med programmene KBBE, ICT og SHH bidrar HEALTH med forskning for å realisere EIP «healthy aging» Viktig å adressere potensielle etiske utfordringer i prosjektet Redusere bruk av forsøksdyr i forskningen Tilstrebe kjønnsbalanse i forskergruppene
Utlysningsteksten (Work Programme 2012) offentliggjøres medio mai CORDIS: http://cordis.europa.eu/fp7/health/home_en.html Søknadsfrister i oktober/november
Health 6. utlysning Underområder som er lukket High-throughput research Pilar 1 Suitability, safety, efficacy of therapies Brain and brain-related diseases Pilar 2 Anti-microbial drug resistance Potentially new and re-emerging epidemics Neglected infectious diseases Cancer Cardiovascular diseases Translating the results of clinical research Pilar 3 outcome into clinical practice Health promotion and prevention
Health 6. utlysning Les WP tekst og retningslinjer som publiseres i mai kast tidligere utgaver Følg krav til søknaden (søknadsfrist, budsjettgrense, sidebegrensning!) Søknader vurderes av eksperter i paneler Tre vurderingskriterier Scientific/technological quality max 5 poeng (terskel 3 eller 4) Implementation and management max 5 poeng Impact max 5 poeng Tilbakemelding til søker Evaluation Summary Report Forhandlinger finansiering i 2-5 år
Health 6. utlysning Antall partnere (utover min. 3) i konsortiet Sammensetning av konsortiet* Prosjektets varighet* bestemmes av søker fleksibelt * Det kan være andre anbefalinger for enkelte tema
1.Biotechnology, generic tools and medical technologies for human health (155 mill. ) Detection, diagnosis and monitoring Development of technologies with a view to patient group stratification for personalised medicine applications Innovative therapeutic approaches and interventions Innovative approaches to solid organ transplantation Medical technology for the transplantation sector and bioartificial organs Innovative strategies for translation of stem cell based therapies in regenerative medicine Targeted nucleic acid delivery as innovative therapeutic or prophylactic approach
2. Translating research for human health (375 mill. ) Integrating biological data and processes: Large-scale data gathering Clinical utility of -omics for better diagnosis and treatment of rare diseases (HIP 30 mill Euro?) Validation of -omics based biomarkers for diseases affecting the elderly Statistical methods for collection and analysis of -omics data Systems biology/medicine SME-driven research applying s.b. to adress medical and clinical needs Applying s.b. approaches for understanding complex human diseases and their co-morbidity Preparing for the future research and innovation activities in systems medicine
2. Translating research for human health (375 mill. ) Research on the brain and related diseases, human development and ageing Human developement and ageing Integrative systems biology and comparative genomics for studying human ageing and/or most common age-related diseases Investigator-driven clinical trials for optimisation of management of elderly patients with multiple diseases
2. Translating research for human health (375 mill. ) Translational research in major infectious diseases: to confront threats to public health Cross cutting Diagnostics for infectious diseases ERA-NET on infectious diseases HIV/AIDS, malaria and tuberculosis Co-infection of HIV/AIDS, malaria, tuberculosis and/or hepatitis Co-morbidity btween infectious and noncommunicable diseases Preventioen and treatment for HIV/AIDS, malaria, tuberculosis Low-cost interventions for disease control in resource poor settings
2. Translating research for human health (375 mill. ) Translational research in other major diseases Diabetes and obesity Innovative approach to manage diabetes Investigator-driven clinical trials for type 1 diabetes research Rare diseases Preclinical and/or clinical developement of substances with a clear potential as orphan drugs Observational trials in rare diseases Bets practice and knowledge sharing in the clinical management of rare diseases
2. Translating research for human health (375 mill. ) Translational research in other major diseases Other chronic diseases Technological approaches to combating sensory impairments Biomarkers and diagnostics for chronic inflammatory diseases of the joints and/or digestive system
3. Optimising the delivery of healthcare to European citizens (50 mill. ) Quality, efficiency and solidarity of healthcare systems including transnational health systems Improving the organisation of health service delivery New methodologies for health technology assessment International public health and health systems Health systems/services research in low and middle income countries
4. Actions across the Health theme (20 mill. ) Coordination and Support Actions Network to encourage knowledge transfer activity in FP-funded health research Training actions linked to intellectual property rights management and knowledge transfer Support for international rare disease research (develop policies and guidelines) Communicating the benefits of European research to the general public
Innovative Medicine Initiative EU Joint Technology Initiative (JTI) 2008-13 http://www.imi.europa.eu/index_en.html Private-Public Partnership (PPP) to share knowledge, efforts and expenses to overcome bottlenecks in the development of new biomedical diagnostics and therapeutics
Innovative Medicine Initiative Projects include basic research on mechanisms, are precompetitive (prior to direct commercial interest) - addressing translational medicine - requiring integrated approaches Budget 2008-13 - 1 bill from EU FP7 Health - 1 bill in kind from EFPIA ( big pharma in Europe) Applicant Consortia - public partners (academia, SMEs, patients org.) - EFPIA private partners ( big pharma )
Innovative Medicine Initiative 4 strategic areas - Safety Evaluation - Efficacy Evaluation - Knowledge Management - Education and Training 5 disease areas - Cancer - Brain disorders - Inflammatory diseases - Metabolic diseases - Infectious diseases 4. utlysning i juni, frist oktober http://www.imi.europa.eu/content/4th-call-2011
FP7 Health 2007 2013 Resultater per 31.12.2010 Sammenlikning nordiske land Ant. søknader Ant. prosjekter Suksessrate (%) DK 444 111 25 FI 366 91 26 NO 224 59 26 SE 754 197 26
2012-utlysninger i andre tematiske programmer med relevans for helse KBBE Food, Agriculture, Fisheries and Biotechnology Food, health, diet-related diseases, consumer behaviour ICT - Information and Communications Technologies Virtual Physiological Human NMP Nanosciences, Nanotechnologies, Materials and new Production Technologies (NMP) Nanotech. systems for diagnosis & treatment, nanomedicine, toxicity of nanoparticles SHH Socioeconomic Sciences and Humanities Making longevity an asset for economic and social development, European childhood and youth survey
FP7 Health 2007 2013 7. utlysning (siste) juli 2012 tentativt: Hjernen og hjernesykdommer Trolig «Year of the Brain» Kreft Hjerte-karsykdommer Vaksiner og medisiner - parasittsykdommer Comparative Effectivness Studies Helseundersøkelser helsefremme/forebygging Stor andel prosjekter med SMB-deltakelse
FP7 Health 2007 2013 Kontaktpersoner NCP Health: Berit Nygaard, 22037174, bn@rcn.no Økonomi og finans: Yngve Foss, 22037375, yf@rcn.no IMI: Hans M. Borchgrevink, 22037160, hmb@rcn.no Research infrastructure: Solveig Flock, 22037034, sfi@rcn.no ERC: Per Ivar Høvring, 22037426 pih@rcn.no SMB: Vebjørn Walderhaug, 22037304, vw@rcn.no Informasjonsdag om 6. utlysning i Brüssel 9. juni
Health - prosjekttyper (funding schemes) Finansieringsform Collaborative Project (Largescale Integrating Project) Minimumsbeløp som søkes fra kommisjonen Maximumsbeløp som søkes fra kommisjonen EUR 6 000 000 EUR 12 000 000 Collaborative Project (Small and medium-scale focussed research Project) EUR 3 000 000 Network of Excellence EUR 12 000 000 Coordination and Support Action (Coordinating Action) Coordination and Support Action (Supporting Actions) EUR 1 500 000 EUR 500 000